Physician profile
Santosh Kumar
NPI 1255530911
$52,780.49
in general payments reported to CMS, 2019-2025
19 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $77.22 · 2021: $11.92 · 2022: $5,821 · 2023: $528 · 2024: $25K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $33K · Travel and Lodging: $6,352 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,500 · Honoraria: $2,175 · Food and Beverage: $2,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $32,755.00 |
| Travel and Lodging | $6,351.82 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,500.00 |
| Honoraria | $2,175.00 |
| Food and Beverage | $2,088.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $24,941.51 | 2022-2025 | Imfinzi, Calquence, Tagrisso |
| Pfizer INC. | $5,373.65 | 2024-2025 | |
| Gilead Sciences, INC. | $5,107.91 | 2021-2025 | Trodelvy |
| Exelixis INC. | $3,948.03 | 2025 | Cabometyx |
| Geron Corporation | $3,551.46 | 2025 | Imetelstat |
| Beigene USA, INC. | $2,575.00 | 2022-2024 | Tevimbra, Brukinsa |
| Springworks Therapeutics, INC. | $2,070.00 | 2024 | Ogsiveo |
| Janssen Biotech, INC. | $1,470.00 | 2024 | Carvykti |
| Novartis Pharmaceuticals Corporation | $1,462.50 | 2025 | |
| Daiichi Sankyo INC. | $1,400.00 | 2022-2025 | Vanflyta |
| Cardinal Health 110 LLC | $275.00 | 2025 | |
| Sobi, INC | $200.00 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $183.78 | 2020-2023 | Opdivo |
| Mirati Therapeutics, INC. | $86.32 | 2023 | Krazati |
| Rigel Pharmaceuticals, INC. | $73.43 | 2023 | Rezlidhia, Tavalisse |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $33.70 | 2020 | |
| Eisai INC. | $15.75 | 2020 | |
| Karyopharm Therapeutics INC. | $12.45 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Santosh Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.